Zegbeh Jallah
Stock Analyst at Capital One
(3.00)
# 1,507
Out of 4,761 analysts
26
Total ratings
34.78%
Success rate
111.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $1.56 | +6,310.26% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.29 | +3,969.18% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $6.15 | +615.45% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $4.45 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $21.85 | +32.72% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $1.25 | +3,740.00% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $8.03 | +771.73% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | $200 → $230 | $0.17 | +131,856.40% | 1 | Sep 23, 2021 | |
| RZLT Rezolute | Initiates: Buy | $21 | $4.53 | +363.58% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $17.77 | +659.71% | 2 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $132 | $3.17 | +4,064.04% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.68 | +782.35% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $10.03 | +448.35% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.84 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.95 | +742.11% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.47 | +4,181.74% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $1.56
Upside: +6,310.26%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.29
Upside: +3,969.18%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $6.15
Upside: +615.45%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $4.45
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $21.85
Upside: +32.72%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $1.25
Upside: +3,740.00%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $8.03
Upside: +771.73%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: $200 → $230
Current: $0.17
Upside: +131,856.40%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $4.53
Upside: +363.58%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $17.77
Upside: +659.71%
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $3.17
Upside: +4,064.04%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.68
Upside: +782.35%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $10.03
Upside: +448.35%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.84
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.95
Upside: +742.11%
Dec 18, 2019
Initiates: Buy
Price Target: $20
Current: $0.47
Upside: +4,181.74%